Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$2.29
+0.4%
$2.57
$1.78
$10.14
$47.73M0.7267,722 shs90,936 shs
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$7.28
-1.5%
$6.28
$3.76
$46.80
$44.49M2.77210,088 shs46,730 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.61
+3.5%
$1.48
$1.10
$2.43
$89.21M2.91142,436 shs66,266 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$15.65
+6.6%
$13.21
$10.80
$17.79
$226.25M-0.0496,113 shs33,457 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$140.56
+1.1%
$139.58
$122.80
$219.34
$4.06B0.67286,672 shs90,546 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
+6.05%-10.24%+3.17%-46.48%-67.29%
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
+2.50%-10.32%+37.11%-2.51%-19.89%
Cellectis S.A. stock logo
CLLS
Cellectis
+1.64%+5.44%+7.12%+23.02%-19.90%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+2.80%-0.61%+8.19%+4.04%+6.77%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+1.13%-3.24%+9.41%-23.20%-23.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4.3193 of 5 stars
3.43.00.04.81.72.50.6
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
4.2001 of 5 stars
3.53.00.04.82.71.70.0
Cellectis S.A. stock logo
CLLS
Cellectis
3.0072 of 5 stars
3.53.00.00.02.52.50.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.5372 of 5 stars
0.01.00.04.62.01.71.3
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.6181 of 5 stars
3.51.00.04.73.12.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.80
Moderate Buy$23.80939.30% Upside
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
3.00
Buy$70.00861.54% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00149.22% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$211.1350.21% Upside

Current Analyst Ratings Breakdown

Latest CLLS, INBX, KRYS, ADVM, and ALGS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.00
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
5/6/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00 ➝ $240.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M47.84N/AN/A$3.40 per share0.67
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$3.94M11.29N/AN/A($7.50) per share-0.97
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M1.81N/AN/A$2.36 per share0.68
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,132.70$130.38 per share0.12$9.23 per share1.70
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M13.98$4.74 per share29.64$32.90 per share4.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/5/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.13N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1633.7813.94N/A37.17%14.64%13.28%8/4/2025 (Estimated)

Latest CLLS, INBX, KRYS, ADVM, and ALGS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/6/2025Q1 2025
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
4/15/2025Q4 2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$1.34-$1.96-$0.62-$1.96N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
3.57
3.57
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/A
7.56
7.56
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
60.43%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.89 million19.64 millionOptionable
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
906.11 million5.82 millionNo Data
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 millionN/AOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable

Recent News About These Companies

Krystal Biotech Q2 EPS Estimate Lowered by HC Wainwright
Krystal Biotech doses first patient in phase 3 trial IOLITE
Krystal Biotech Inc News (KRYS) - Investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$2.29 +0.01 (+0.44%)
As of 02:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aligos Therapeutics stock logo

Aligos Therapeutics NASDAQ:ALGS

$7.28 -0.11 (-1.49%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.60 +0.06 (+3.55%)
As of 02:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$15.64 +0.98 (+6.65%)
As of 02:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$140.56 +1.55 (+1.11%)
As of 02:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.